News Channels

15 Apr 2019 Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
15 Apr 2019 Promethera Biosciences Presents Updated Phase 2a Results for World’s First Stem Cell Clinical Trial in ACLF at The International Liver Congress™/ EASL 2019
15 Apr 2019 Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
15 Apr 2019 Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD
13 Apr 2019 Spring Bank Announces Positive Results from the Recently Completed Phase 2 Chronic Hepatitis B ACHIEVE Trial and Additional Inarigivir Studies
13 Apr 2019 TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial Based on the Recommendation of the Independent Data Monitoring Committee
13 Apr 2019 CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress™ 2019
13 Apr 2019 Albireo Presents Data on A4250 in Children with Biliary Atresia and Alagille Syndrome at The International Liver Congress 2019
13 Apr 2019 Cirius Therapeutics Announces Presentation of Interim Data from Phase 2b Clinical Study of MSDC-0602K at The International Liver Congress 2019
13 Apr 2019 Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
13 Apr 2019 Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
13 Apr 2019 Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™
13 Apr 2019 Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™
13 Apr 2019 BALVERSA™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations
12 Apr 2019 Gyroscope Therapeutics merges with Orbit Biomedical creating a leading retinal gene therapy company
12 Apr 2019 Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019
12 Apr 2019 Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
12 Apr 2019 Trogarzo® Receives Positive Recommendation from Scientific Advisory Group of CHMP in Europe
12 Apr 2019 89bio Announces Preclinical Data That Demonstrate Potential Utility of BIO89-100 for Treatment of NASH
12 Apr 2019 Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up